On Nov 09, major Wall Street analysts update their ratings for $Ligand Pharmaceuticals (LGND.US)$, with price targets ranging from $135 to $150.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $125 to $150.
Oppenheimer analyst Leland Gershell maintains with a buy rating, and adjusts the target price from $135 to $147.
Oppenheimer analyst Trevor Allred initiates coverage with a buy rating, and sets the target price at $147.
Craig-Hallum analyst Matt Hewitt maintains with a buy rating, and sets the target price at $140.
Benchmark Co. analyst Robert Wasserman maintains with a buy rating, and adjusts the target price from $110 to $135.
Furthermore, according to the comprehensive report, the opinions of $Ligand Pharmaceuticals (LGND.US)$'s main analysts recently are as follows:
Following a quarter that outperformed expectations and led to raised forecasts, it's noted that the company's positive outlook is supported by robust performance across its three principal revenue channels.
Ligand's third-quarter financial outcomes surpassed expectations on the revenue front, and the company has elevated its full-year revenue forecast for fiscal year 2024 to a range of $160 million to $165 million. This projection is deemed cautious by analysts in light of the robust performance of royalty assets, coupled with the acceleration of early product launches and the possibility of expanded usage for various indications.
Here are the latest investment ratings and price targets for $Ligand Pharmaceuticals (LGND.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月9日，多家華爾街大行更新了$Ligand Pharmaceuticals (LGND.US)$的評級，目標價介於135美元至150美元。
巴克萊銀行分析師Balaji Prasad維持買入評級，並將目標價從125美元上調至150美元。
奧本海默控股分析師Leland Gershell維持買入評級，並將目標價從135美元上調至147美元。
奧本海默控股分析師Trevor Allred首次給予買入評級，目標價147美元。
Craig-Hallum分析師Matt Hewitt維持買入評級，目標價140美元。
本臻力行分析師Robert Wasserman維持買入評級，並將目標價從110美元上調至135美元。
此外，綜合報道，$Ligand Pharmaceuticals (LGND.US)$近期主要分析師觀點如下：
以下爲今日5位分析師對$Ligand Pharmaceuticals (LGND.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
